openPR Logo
Press release

Rare Kidney Diseases Market Share Analysis, Growth And Forecast 2033

12-07-2024 10:44 AM CET | Health & Medicine

Press release from: The Business research company

Rare Kidney Diseases Market Share

Rare Kidney Diseases Market Share

The Business Research Company recently released a comprehensive report on the Global Rare Kidney Diseases Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

According to The Business Research Company's, The rare kidney diseases market size has grown rapidly in recent years. It will grow from $2.52 billion in 2023 to $2.8 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to increased disease recognition, orphan drug designations, patient advocacy and awareness, global collaborations in research..

The rare kidney diseases market size is expected to see strong growth in the next few years. It will grow to $4.07 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to emergence of gene therapies, increasing investment in rare disease research, growing collaboration between stakeholders, global initiatives for rare diseases.. Major trends in the forecast period include patient-centric approach, real-world evidence and data analytics, regulatory developments, telemedicine and remote monitoring, global health initiatives..

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Market Drivers and Trends:

Government initiatives and funding for kidney disorders are expected to propel the growth of the rare kidney disease market going forward. A government initiative and funding are a type of government financial support given to selected entities with ideas or projects that contribute to and improve public services and the economy. The government provides aid in kidney disorders to enhance disease surveillance and improve the quality of life for persons with various kidney diseases by using a comprehensive public health strategy that includes other public health agencies and national organizations. For instance, in July 2022, The United States House Committee on Appropriations, a US-based committee of the House of Representatives, initiated various investment programs to promote kidney health. It includes $8.5 million in funding for the Centers for Disease Control and Prevention's (CDC) chronic kidney disease program to accelerate activities to promote regular kidney disease awareness, diagnosis, and treatment. Further, a living donation investment of $1 million was made to boost the national living donor assistance center, bringing the total to $8 million in ongoing investment in innovation and research. Therefore, government initiatives and funding for kidney disorders are driving the growth of the rare kidney disease market.

Product innovation is a key trend gaining popularity in the rare kidney disease market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in September 2022, STADA Arzneimittel AG, a Germany-based company operating in generics, specialty pharma, and non-prescription consumer healthcare products, introduced Kinpeygo (budesonide), the first medicine authorized in the EU for treating rare kidney disease for treating a rare kidney disease immunoglobulin A nephropathy (IgAN). The modified-release budesonide capsules are the first and only approved treatment in the EU for primary IgAN, a rare, progressive autoimmune kidney disease with a high unmet need, with more than 25%-30% of patients eventually developing terminal kidney insufficiency requiring dialysis or kidney transplantation.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, GlaxoSmithKline plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Proteostasis Therapeutics, Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., Spyryx Biosciences Inc., OxThera AB, Advicenne Pharma SA, ProQR Therapeutics NV, Reata Pharmaceuticals Inc., Savara Inc.

Rare Kidney Diseases Market 2024 Key Insights:

• The rare kidney diseases market size is expected to see strong growth in the next few years. It will grow to $4.07 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%.
• Government Catalysts Fueling Rare Kidney Disease Market Surge
• Innovative Therapies Emerge As Key Catalysts In Rare Kidney Disease Market Evolution
• North America was the leading region in the rare kidney disease market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=11908&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rare Kidney Diseases Market Share Analysis, Growth And Forecast 2033 here

News-ID: 3777112 • Views:

More Releases from The Business research company

2025-2034 Wearable Fitness Trackers Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights
2025-2034 Wearable Fitness Trackers Market Outlook: Key Drivers, Emerging Challe …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Wearable Fitness Trackers Industry Market Size Be by 2025? The market for wearable fitness monitoring devices has experienced significant expansion lately, projected to move from a valuation of $51.28 billion in 2024 to $60.04 billion by 2025, reflecting a compound annual growth rate (CAGR) of 17.1%.
Key Factor Supporting Global Spatial Genomics And Transcriptomics Market Development in 2025: Rising Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To Its Role In Enabling Targeted, Gene-Based Therapies
Key Factor Supporting Global Spatial Genomics And Transcriptomics Market Develop …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Spatial Genomics And Transcriptomics Market Size By 2025? The overall valuation of the spatial genomics and transcriptomics sector has experienced a swift ascent lately, projected to advance from its 2024 benchmark of $1.51 billion to $1.7 billion by 2025, reflecting a compound annual growth rate
Emerging Trends to Drive Point Of Care Infectious Disease Testing Market Growth at 13.6% CAGR Through 2029
Emerging Trends to Drive Point Of Care Infectious Disease Testing Market Growth …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Point Of Care Infectious Disease Testing Market Size Growth Forecast: What to Expect by 2025? The market encompassing point-of-care testing for infectious diseases has experienced swift expansion lately, projected to increase its valuation from $4.21 billion at the close of 2024 to $4.78 billion by 2025, reflecting a compound
Emerging Trends to Reshape the Global Pernicious Anemia Diagnosis And Treatment Market: Advancements In B12 Maintenance Therapy To Enhance Patient Adherence And Outcomes as a Key Influencer
Emerging Trends to Reshape the Global Pernicious Anemia Diagnosis And Treatment …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Pernicious Anemia Diagnosis And Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market associated with pernicious anemia diagnosis and subsequent therapy has experienced robust expansion over the past few years, projected to advance from a value of $1.42 billion in 2024 to $1.51

All 5 Releases


More Releases for Disease

Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research. Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight: Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and